Istanbul, Turkey, 15th September 2009 – Further evidence of the superior antidepressant efficacy of Valdoxan®/Thymanax® (agomelatine) over conventional selective serotonin reuptake inhibitors (SSRIs) and serotonin noradrenalin reuptake inhibitor (SNRI) antidepressants was presented today at the Servier satellite symposium on the occasion of the 22nd European College of Neuropsychopharmacology (ECNP) Congress, with educational financial support provided [...]

Welcome to the www.valdoxan.com website.
By using this site you acknowledge having read the legal notice and you undertake to comply with it. The content of this document may undergo changes; consequently we invite you to consult the legal notice regularly.
1. Legal notice
This site is owned by LES LABORATOIRES SERVIER, a company with a share capital [...]

Valdoxan 25 mg film-coated tablets
Agomelatine
Read all of this leaflet carefully before you start taking this medicine.
- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor or pharmacist.
- This medicine has been prescribed for you. Do not pass it on to others. It may harm them, [...]

Servier
The Servier’s corporate website.

Dialogues in Clinical Neuroscience
The electronic version of the Dialogues in Clinical Neuroscience journal.

Medicographia
The electronic version or The Medicographia journal.

1. NAME OF THE MEDICINAL PRODUCT
2. QUALITATIVE AND QUANTITATIVE COMPOSITION
3. PHARMACEUTICAL FORM
4. CLINICAL PARTICULARS
4.1 Therapeutic indications
4.2 Posology and method of administration
4.3 Contraindications
4.4 Special warnings and precautions for use
[...]

1. What is the clinical proof of VALDOXAN’s antidepressant efficacy?
The antidepressant efficacy of VALDOXAN has been confirmed in four trials versus placebo, three over the short term and one over the long term. The antidepressant efficacy of VALDOXAN is significantly superior to that of placebo, as mentioned in the Valdoxan SPC, whatever the symptom intensity, [...]

Valdoxan is a novel antidepressant indicated in the treatment of major depressive episodes in adults. The recommended dose of Valdoxan is 1 tablet of 25 mg once daily, taken orally at bedtime. After 2 weeks of treatment, if there is no improvement of symptoms, the dose of Valdoxan may be increased to 50 mg once [...]

Valdoxan, the first melatonergic antidepressant, presents an innovative receptor profile and mode of action. Valdoxan is a melatonergic agonist (MT1 and MT2 receptors) and 5-HT2C antagonist. Valdoxan resynchronizes circadian rhythms in animal models of circadian rhythm disruption.
Innovative receptor profile of Valdoxan
Valdoxan is the first melatonergic antidepressant.
Valdoxan is a melatonergic agonist (MT1 and MT2 receptors) and [...]

Valdoxan is effective whatever the intensity of depressive symptoms. The efficacy of Valdoxan was observed in the more severely depressed patients (baseline HAM-D ≥ 25) in all positive placebo-controlled studies.
Efficacy of Valdoxan in severe depression
Results of the meta-analysis of three positive, randomized, double-blind, placebo controlled studies in 357 patients treated with Valdoxan and 360 patients [...]

Valdoxan provides MDD patients with a significant symptomatic relief, as demonstrated by well-documented improvements in depressed mood, anxiety symptoms, and also sleep-wake disturbances (daytime impairment and sleep disturbances).
Efficacy of Valdoxan on depressed mood
Valdoxan has been demonstrated to be significantly effective in relieving depressed mood of patients with MDD, the most characteristic symptom of depression.
In a [...]